NAYAX LTD (NYAX)

IL0011751166 - Common Stock

28.69  +1.39 (+5.09%)

Fundamental Rating

3

Overall NYAX gets a fundamental rating of 3 out of 10. We evaluated NYAX against 124 industry peers in the Electronic Equipment, Instruments & Components industry. NYAX may be in some trouble as it scores bad on both profitability and health. NYAX is valued quite expensive, but it does show an excellent growth.



1

1. Profitability

1.1 Basic Checks

NYAX had negative earnings in the past year.
NYAX had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NYAX reported negative operating cash flow in multiple years.

1.2 Ratios

NYAX has a Return On Assets of -3.93%. This is comparable to the rest of the industry: NYAX outperforms 43.90% of its industry peers.
The Return On Equity of NYAX (-10.04%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -3.93%
ROE -10.04%
ROIC N/A
ROA(3y)-10.88%
ROA(5y)-9.39%
ROE(3y)-23.64%
ROE(5y)-31.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NYAX's Gross Margin of 37.49% is fine compared to the rest of the industry. NYAX outperforms 64.23% of its industry peers.
NYAX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NYAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.38%
GM growth 5Y-3.01%

2

2. Health

2.1 Basic Checks

NYAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NYAX has more shares outstanding than it did 1 year ago.
NYAX has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.99 indicates that NYAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
NYAX has a Altman-Z score (2.99) which is in line with its industry peers.
A Debt/Equity ratio of 0.39 indicates that NYAX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.39, NYAX is not doing good in the industry: 67.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 2.99
ROIC/WACCN/A
WACC9.3%

2.3 Liquidity

NYAX has a Current Ratio of 1.36. This is a normal value and indicates that NYAX is financially healthy and should not expect problems in meeting its short term obligations.
NYAX's Current ratio of 1.36 is on the low side compared to the rest of the industry. NYAX is outperformed by 86.18% of its industry peers.
A Quick Ratio of 1.27 indicates that NYAX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.27, NYAX is not doing good in the industry: 72.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.84% over the past year.
NYAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.72%.
The Revenue has been growing by 37.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)49.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%121.51%
Revenue 1Y (TTM)35.72%
Revenue growth 3Y44.05%
Revenue growth 5Y37.05%
Sales Q2Q%37.6%

3.2 Future

Based on estimates for the next years, NYAX will show a very strong growth in Earnings Per Share. The EPS will grow by 70.19% on average per year.
NYAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.41% yearly.
EPS Next Y46.54%
EPS Next 2Y69.61%
EPS Next 3Y70.19%
EPS Next 5YN/A
Revenue Next Year38.74%
Revenue Next 2Y33.76%
Revenue Next 3Y32.41%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYAX. In the last year negative earnings were reported.
NYAX is valuated quite expensively with a Price/Forward Earnings ratio of 68.60.
NYAX's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.00, NYAX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 68.6

4.2 Price Multiples

NYAX's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1598.16

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NYAX's earnings are expected to grow with 70.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.61%
EPS Next 3Y70.19%

0

5. Dividend

5.1 Amount

No dividends for NYAX!.
Industry RankSector Rank
Dividend Yield N/A

NAYAX LTD

NASDAQ:NYAX (11/21/2024, 8:00:02 PM)

28.69

+1.39 (+5.09%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.03B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 68.6
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.93%
ROE -10.04%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 37.49%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)49.84%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y46.54%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)35.72%
Revenue growth 3Y44.05%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y